Ludwig Institute for Cancer Research appoints scientific director

Chi Van Dang, MD, has been appointed scientific director of Ludwig Institute for Cancer Research.

Dang will oversee execution of Ludwig’s scientific strategy to advance cancer prevention, diagnosis and treatment efforts.

Chi Van Dang

“We are very pleased to have Dr. Dang onboard and have every confidence that his scientific insight and experience leading some of the best research institutions in the world will be of great benefit to Ludwig,” John L. Notter, chairman of the board of Ludwig Institute for Cancer Research, said in a press release.

Dang, a hematologist–oncologist and widely respected researcher, served as director of University of Pennsylvania Perelman School of Medicine’s Abramson Cancer Center since 2011. He previously served as vice dean for research and director of the Hopkins Institute for Cell Engineering at Johns Hopkins University.

“Ludwig has a rich history of discovery in basic and translational cancer research and I am excited and honored by the opportunity to lead its network of accomplished scientists,” Dang said in the release. “We are today at a unique place in the history of this field, in which advances in a variety of biomedical disciplines are converging at an unprecedented rate to revolutionize our understanding of cancer. Ludwig is well positioned to take advantage of this phenomenon, as many of its scientists and research groups are playing a leading role in driving this convergence. I look forward to working with Ludwig researchers across institutions and disciplines, drawing on each group’s expertise and interests to forge collaborations aimed at solving specific and significant challenges of cancer research — and to translating their insights into therapies and diagnostics that will benefit patients.”

 

Chi Van Dang, MD, has been appointed scientific director of Ludwig Institute for Cancer Research.

Dang will oversee execution of Ludwig’s scientific strategy to advance cancer prevention, diagnosis and treatment efforts.

Chi Van Dang

“We are very pleased to have Dr. Dang onboard and have every confidence that his scientific insight and experience leading some of the best research institutions in the world will be of great benefit to Ludwig,” John L. Notter, chairman of the board of Ludwig Institute for Cancer Research, said in a press release.

Dang, a hematologist–oncologist and widely respected researcher, served as director of University of Pennsylvania Perelman School of Medicine’s Abramson Cancer Center since 2011. He previously served as vice dean for research and director of the Hopkins Institute for Cell Engineering at Johns Hopkins University.

“Ludwig has a rich history of discovery in basic and translational cancer research and I am excited and honored by the opportunity to lead its network of accomplished scientists,” Dang said in the release. “We are today at a unique place in the history of this field, in which advances in a variety of biomedical disciplines are converging at an unprecedented rate to revolutionize our understanding of cancer. Ludwig is well positioned to take advantage of this phenomenon, as many of its scientists and research groups are playing a leading role in driving this convergence. I look forward to working with Ludwig researchers across institutions and disciplines, drawing on each group’s expertise and interests to forge collaborations aimed at solving specific and significant challenges of cancer research — and to translating their insights into therapies and diagnostics that will benefit patients.”